BR112015013136B1 - Dispositivos de filtração posicionáveis in vivo - Google Patents
Dispositivos de filtração posicionáveis in vivo Download PDFInfo
- Publication number
- BR112015013136B1 BR112015013136B1 BR112015013136-0A BR112015013136A BR112015013136B1 BR 112015013136 B1 BR112015013136 B1 BR 112015013136B1 BR 112015013136 A BR112015013136 A BR 112015013136A BR 112015013136 B1 BR112015013136 B1 BR 112015013136B1
- Authority
- BR
- Brazil
- Prior art keywords
- filtration
- therapeutic agent
- frame structure
- catheter
- filtration device
- Prior art date
Links
- 238000001914 filtration Methods 0.000 claims abstract description 338
- 239000000463 material Substances 0.000 claims abstract description 196
- 239000003814 drug Substances 0.000 claims abstract description 154
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 136
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 76
- 239000008280 blood Substances 0.000 claims abstract description 65
- 210000004369 blood Anatomy 0.000 claims abstract description 65
- 238000001727 in vivo Methods 0.000 claims abstract description 30
- 239000012528 membrane Substances 0.000 claims description 132
- 239000011347 resin Substances 0.000 claims description 53
- 229920005989 resin Polymers 0.000 claims description 53
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 34
- 239000002246 antineoplastic agent Substances 0.000 claims description 32
- 229940127089 cytotoxic agent Drugs 0.000 claims description 32
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 230000003197 catalytic effect Effects 0.000 claims description 12
- 230000017531 blood circulation Effects 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 9
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000003456 ion exchange resin Substances 0.000 claims description 7
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 7
- 238000005341 cation exchange Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 4
- 239000002952 polymeric resin Substances 0.000 claims description 4
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 230000001453 nonthrombogenic effect Effects 0.000 claims description 2
- 241000047703 Nonion Species 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 20
- 238000011144 upstream manufacturing Methods 0.000 abstract description 13
- 210000001519 tissue Anatomy 0.000 description 47
- 239000002245 particle Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 17
- 210000000056 organ Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 210000002796 renal vein Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- -1 cyclic oligosaccharides Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000004731 jugular vein Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002989 hepatic vein Anatomy 0.000 description 4
- 229910001092 metal group alloy Inorganic materials 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003575 carbonaceous material Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 238000009432 framing Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 229920006163 vinyl copolymer Polymers 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 101710106950 Long neurotoxin 2 Proteins 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000003129 brachiocephalic vein Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- QHIWVLPBUQWDMQ-UHFFFAOYSA-N butyl prop-2-enoate;methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C.CCCCOC(=O)C=C QHIWVLPBUQWDMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 1
- LLUBWNFGQWPGSA-UHFFFAOYSA-N ethenyl prop-2-enoate;sodium Chemical compound [Na].C=COC(=O)C=C LLUBWNFGQWPGSA-UHFFFAOYSA-N 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 229940010746 sotradecol Drugs 0.000 description 1
- 210000000798 superior sagittal sinus Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000001782 transverse sinus Anatomy 0.000 description 1
- 108010078742 trisacryl gelatin microspheres Proteins 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3615—Cleaning blood contaminated by local chemotherapy of a body part temporarily isolated from the blood circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/013—Distal protection devices, i.e. devices placed distally in combination with another endovascular procedure, e.g. angioplasty or stenting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/0105—Open ended, i.e. legs gathered only at one side
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/0108—Both ends closed, i.e. legs gathered at both ends
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/011—Instruments for their placement or removal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/013—Distal protection devices, i.e. devices placed distally in combination with another endovascular procedure, e.g. angioplasty or stenting
- A61F2002/015—Stop means therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0067—Three-dimensional shapes conical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1097—Balloon catheters with special features or adapted for special applications with perfusion means for enabling blood circulation only while the balloon is in an inflated state, e.g. temporary by-pass within balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M25/0029—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the middle part of the catheter, e.g. slots, flaps, valves, cuffs, apertures, notches, grooves or rapid exchange ports
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Surgical Instruments (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745183P | 2012-12-21 | 2012-12-21 | |
| US61/745,183 | 2012-12-21 | ||
| US201361784507P | 2013-03-14 | 2013-03-14 | |
| US61/784,507 | 2013-03-14 | ||
| PCT/US2013/076159 WO2014100201A1 (en) | 2012-12-21 | 2013-12-18 | In vivo positionable filtration devices and methods related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015013136A2 BR112015013136A2 (pt) | 2017-07-11 |
| BR112015013136B1 true BR112015013136B1 (pt) | 2021-08-31 |
Family
ID=50979156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015013136-0A BR112015013136B1 (pt) | 2012-12-21 | 2013-12-18 | Dispositivos de filtração posicionáveis in vivo |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11406485B2 (https=) |
| EP (1) | EP2934376B1 (https=) |
| JP (1) | JP6420255B2 (https=) |
| CN (1) | CN104812336B (https=) |
| AU (1) | AU2013361551B2 (https=) |
| BR (1) | BR112015013136B1 (https=) |
| CA (1) | CA2895799C (https=) |
| WO (1) | WO2014100201A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050153309A1 (en) | 2003-12-22 | 2005-07-14 | David Hoon | Method and apparatus for in vivo surveillance of circulating biological components |
| US10272182B2 (en) * | 2014-10-10 | 2019-04-30 | The Regents Of The University Of California | Copolymer membrane for high-dose chemotherapy delivery during transarterial chemoembolization |
| WO2016134047A1 (en) * | 2015-02-17 | 2016-08-25 | The Regents Of The University Of California | Magnetic filtration devices and methods related thereto |
| WO2017027754A1 (en) * | 2015-08-12 | 2017-02-16 | The Regents Of The University Of California | Filtration devices and methods related thereto |
| US10052108B2 (en) | 2015-10-30 | 2018-08-21 | Incumedx, Inc. | Devices and methods for delivering an implant to a vascular disorder |
| US11090055B2 (en) | 2015-10-30 | 2021-08-17 | Incumedx Inc. | Devices and methods for delivering an implant to a vascular disorder |
| US11071812B2 (en) * | 2016-05-31 | 2021-07-27 | Penumbra, Inc. | Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood |
| SG11201810969RA (en) | 2016-06-09 | 2019-01-30 | Haimachek Inc | Collector for detection and reversible capturing of cells from body fluids in vivo |
| CN107638602B (zh) * | 2017-10-20 | 2024-07-23 | 西安蓝晓科技新材料股份有限公司 | 一种放置在血管中的过滤器及制备方法和应用 |
| US20210228327A1 (en) * | 2018-04-30 | 2021-07-29 | The Regents Of The University Of California | Three-dimensional printed scaffold for capturing toxins and releasing agents |
| WO2021155912A1 (en) * | 2020-02-04 | 2021-08-12 | Clearstream Technologies Limited | Embolisation system for promoting clot formation |
| JP2024542593A (ja) * | 2021-11-29 | 2024-11-15 | サイトソーベンツ・コーポレーション | がん免疫療法治療の改善 |
| WO2024072901A1 (en) * | 2022-09-28 | 2024-04-04 | Sigyn Therapeutics, Inc. | System and methods to enhance chemotherapy delivery and reduce toxicity |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5069662A (en) * | 1988-10-21 | 1991-12-03 | Delcath Systems, Inc. | Cancer treatment |
| US5549626A (en) | 1994-12-23 | 1996-08-27 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Vena caval filter |
| US6022336A (en) * | 1996-05-20 | 2000-02-08 | Percusurge, Inc. | Catheter system for emboli containment |
| US5800517A (en) | 1996-08-19 | 1998-09-01 | Scimed Life Systems, Inc. | Stent delivery system with storage sleeve |
| US5814064A (en) * | 1997-03-06 | 1998-09-29 | Scimed Life Systems, Inc. | Distal protection device |
| US6361545B1 (en) * | 1997-09-26 | 2002-03-26 | Cardeon Corporation | Perfusion filter catheter |
| JP2002543877A (ja) * | 1999-05-07 | 2002-12-24 | サルヴィアック・リミテッド | 塞栓防止器具 |
| US6511503B1 (en) * | 1999-12-30 | 2003-01-28 | Advanced Cardiovascular Systems, Inc. | Catheter apparatus for treating occluded vessels and filtering embolic debris and method of use |
| ES2282246T3 (es) * | 2000-03-10 | 2007-10-16 | Anthony T. Don Michael | Dispositivo de prevencion de la embolia vascular que utiliza filtros. |
| EP1312387B1 (en) * | 2000-08-25 | 2014-05-21 | Kaneka Corporation | Method for removal of bacterial toxins from a bacterial toxin-containing fluid |
| CA2430554A1 (en) | 2000-12-01 | 2002-07-25 | Nephros Therapeutics, Inc. | Intravascular blood conditioning device and use thereof |
| US6596011B2 (en) * | 2001-06-12 | 2003-07-22 | Cordis Corporation | Emboli extraction catheter and vascular filter system |
| US20030109824A1 (en) * | 2001-11-07 | 2003-06-12 | Microvena Corporation | Distal protection device with local drug delivery to maintain patency |
| US20040064099A1 (en) * | 2002-09-30 | 2004-04-01 | Chiu Jessica G. | Intraluminal needle injection substance delivery system with filtering capability |
| US7481823B2 (en) * | 2002-10-25 | 2009-01-27 | Boston Scientific Scimed, Inc. | Multiple membrane embolic protection filter |
| CN1244313C (zh) * | 2003-01-07 | 2006-03-08 | 周星 | 可回收血管滤器 |
| US7163549B2 (en) * | 2003-02-11 | 2007-01-16 | Boston Scientific Scimed Inc. | Filter membrane manufacturing method |
| US7137991B2 (en) * | 2003-02-24 | 2006-11-21 | Scimed Life Systems, Inc. | Multi-wire embolic protection filtering device |
| EP1644077A4 (en) * | 2003-03-18 | 2012-01-04 | Catharos Medical Systems Inc | METHOD AND DEVICES FOR OBTAINING A MEDICAL AGENT FROM A PHYSIOLOGICAL EFFERENT LIQUID COLLECTOR |
| US20060149312A1 (en) * | 2004-12-30 | 2006-07-06 | Edward Arguello | Distal protection device with improved wall apposition |
| US7837702B2 (en) * | 2005-12-21 | 2010-11-23 | Nexeon Medsystems, Inc. | Interventional catheter for retrograde use having embolic protection capability and methods of use |
| US20120035434A1 (en) * | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Control of a lumen traveling device in a body tube tree |
| CA2661221C (en) * | 2006-08-24 | 2014-03-18 | Fresenius Medical Care Holdings, Inc. | Device for removing fluid from blood in a patient |
| US8876754B2 (en) * | 2006-08-31 | 2014-11-04 | Bayer Medical Care Inc. | Catheter with filtering and sensing elements |
| US20100106181A1 (en) * | 2007-01-08 | 2010-04-29 | Yossi Gross | In-situ filter |
| CN101491465A (zh) | 2008-01-21 | 2009-07-29 | 微创医疗器械(上海)有限公司 | 一种血管滤器 |
| JP5391407B2 (ja) | 2008-04-03 | 2014-01-15 | クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニー | 自浄式装置、システムおよびその使用方法 |
| US8246565B2 (en) * | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
| US8607989B2 (en) | 2009-06-15 | 2013-12-17 | Vascular Vision Pharmaceutical Co. | Filter composites for drug detoxification |
| US8696698B2 (en) * | 2009-12-02 | 2014-04-15 | Surefire Medical, Inc. | Microvalve protection device and method of use for protection against embolization agent reflux |
| AU2011224640B2 (en) * | 2010-03-06 | 2015-05-07 | Nfusion Vascular Systems, Llc | Recovery catheter assembly |
| WO2011133287A1 (en) | 2010-04-19 | 2011-10-27 | The Trustees Of Columbia University In The City Of New York | Portable blood filtration devices, systems, and methods |
| CN101843531A (zh) * | 2010-05-25 | 2010-09-29 | 天健医疗科技(苏州)有限公司 | 一种药物包被血栓过滤器 |
| ES3029850T3 (en) * | 2011-03-09 | 2025-06-25 | Neuravi Ltd | A clot retrieval device for removing occlusive clot from a blood vessel |
| US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
| EP2749309B1 (en) * | 2012-12-28 | 2016-04-27 | Cook Medical Technologies LLC | Ion exchange ureteral stent |
-
2013
- 2013-12-18 CN CN201380061710.9A patent/CN104812336B/zh active Active
- 2013-12-18 BR BR112015013136-0A patent/BR112015013136B1/pt active IP Right Grant
- 2013-12-18 AU AU2013361551A patent/AU2013361551B2/en active Active
- 2013-12-18 EP EP13864473.7A patent/EP2934376B1/en active Active
- 2013-12-18 CA CA2895799A patent/CA2895799C/en active Active
- 2013-12-18 JP JP2015549633A patent/JP6420255B2/ja active Active
- 2013-12-18 US US14/649,838 patent/US11406485B2/en active Active
- 2013-12-18 WO PCT/US2013/076159 patent/WO2014100201A1/en not_active Ceased
-
2022
- 2022-07-08 US US17/860,574 patent/US12036348B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2895799A1 (en) | 2014-06-26 |
| EP2934376A1 (en) | 2015-10-28 |
| US12036348B2 (en) | 2024-07-16 |
| AU2013361551B2 (en) | 2018-03-22 |
| HK1209018A1 (en) | 2016-03-24 |
| US20220338972A1 (en) | 2022-10-27 |
| CN104812336B (zh) | 2018-06-15 |
| US11406485B2 (en) | 2022-08-09 |
| CN104812336A (zh) | 2015-07-29 |
| WO2014100201A1 (en) | 2014-06-26 |
| CA2895799C (en) | 2021-09-28 |
| JP2016501633A (ja) | 2016-01-21 |
| US20150305850A1 (en) | 2015-10-29 |
| JP6420255B2 (ja) | 2018-11-07 |
| EP2934376A4 (en) | 2016-07-06 |
| AU2013361551A1 (en) | 2015-06-04 |
| BR112015013136A2 (pt) | 2017-07-11 |
| EP2934376B1 (en) | 2018-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12036348B2 (en) | In vivo positionable filtration devices and methods related thereto | |
| US8827943B2 (en) | Catheter | |
| ES2736176T3 (es) | Aparato de filtro y armazón y método de uso | |
| ES2625510T3 (es) | Sistema de soporte hepático | |
| ES2651948T3 (es) | Administración de un polímero adsorbente para el tratamiento de la inflamación sistémica | |
| WO2002072172A2 (en) | Apparatus and methods for capture of medical agents | |
| US11071812B2 (en) | Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood | |
| DE102017113853A1 (de) | Hämokompatibler Adsorber zur Dialyse proteingebundener Urämietoxine | |
| Furuyoshi et al. | New Adsorption Column (Lixelle) to Eliminate (β2‐Microglobulin for Direct Hemoperfusion | |
| JP2022542517A (ja) | 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 | |
| US20230225850A1 (en) | Filtration devices and methods related thereto | |
| HK1209018B (zh) | 体内可定位过滤装置及其相关方法 | |
| CN121586609A (zh) | 过滤装置和用于使用该过滤装置的系统和方法 | |
| ES2935909T3 (es) | Dispositivo para la eliminación selectiva de moléculas de tejidos o fluidos | |
| Hew et al. | Liver support systems: The low clearance of model hepatic excretory anions by charcoal hemoperfusion | |
| JP3333631B2 (ja) | 保存血液製剤用輸血システム | |
| Hartmann et al. | Particle leakage in extracorporeal blood purification systems based on microparticle suspensions | |
| JP4141224B2 (ja) | 低密度リポ蛋白およびフィブリノーゲンの吸着材、及びその吸着器 | |
| JP2007105241A (ja) | 造影剤除去システムの作動方法 | |
| de Koning et al. | Coating Membranes for a Sorbent‐Based Artificial Liver: Adsorption Characteristics | |
| JP2018203709A (ja) | Ａβ除去システム | |
| JP2007089768A (ja) | 造影剤除去システム | |
| JP2009077837A (ja) | 造影剤除去システム | |
| JP2006263455A (ja) | 造影剤除去システム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |